Merck EVP gets stock options and RSU awards

Oosthuizen Johannes Jacobus reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Oosthuizen Johannes Jacobus reported acquisition or exercise transactions in this Form 4 filing.

Merck & Co., Inc. executive vice president for Oncology & International, Johannes Jacobus Oosthuizen, reported new equity awards. He received a grant of 31,044 stock options, each allowing him to buy Merck common stock at $113.15 per share, expiring in 2036 and vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. He was also granted 10,605 restricted stock units, each representing a right to receive one Merck share, vesting and settling in stock in three equal installments on the same dates. Following these awards, he directly holds 21,895.389 shares of Merck common stock.

Insider Trade Summary

Grant/Award: 41,649 shares

Grant/Award 3 txns

Insider Oosthuizen Johannes Jacobus

Role EVP, Oncology & Int?l

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	10,605	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	31,044	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Unit — 10,605 contracts (Direct); Stock Option (Right to Buy) — 31,044 contracts (Direct); Common Stock — 21,895.389 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
2. F2. These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
3. F3. The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.

Key Figures

Stock options granted: 31,044 options Option exercise price: $113.15 per share Option expiration: 5/4/2036 +3 more

6 metrics

Stock options granted 31,044 options Grant to EVP on 5/5/2026

Option exercise price $113.15 per share Stock Option (Right to Buy)

Option expiration 5/4/2036 Expiration date of granted options

RSUs granted 10,605 units Restricted Stock Unit award on 5/5/2026

RSU vesting schedule 3 equal installments Vest on 5/5/2027, 5/5/2028, 5/5/2029

Common stock held 21,895.389 shares Direct holdings after transactions

Key Terms

Restricted Stock Unit, Stock Option (Right to Buy), vests and becomes exercisable, contingent right, +1 more

5 terms

Restricted Stock Unit financial

"Restricted Stock Unit, each representing a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with an exercise price of 113.1500"

vests and becomes exercisable financial

"The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and 5/5/2029"

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

distributed as shares financial

"These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Merck (MRK) EVP Johannes Oosthuizen receive in this Form 4?

Johannes Oosthuizen received a grant of 31,044 stock options and 10,605 restricted stock units. The options allow future purchases at $113.15 per share, while the RSUs convert into an equal number of Merck common shares as they vest.

What are the vesting dates for Johannes Oosthuizen’s new Merck (MRK) stock options?

The 31,044 stock options vest in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. Once vested, the options become exercisable, allowing Oosthuizen to buy Merck common stock at the fixed $113.15 exercise price through 2036.

How do the restricted stock units (RSUs) from Merck’s Form 4 convert into shares?

Each of the 10,605 restricted stock units represents a contingent right to receive one Merck common share. The RSUs vest and are distributed as shares in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, subject to continued service conditions.

What is the exercise price and expiration date of Johannes Oosthuizen’s new Merck stock options?

The newly granted stock options have an exercise price of $113.15 per share and expire on 5/4/2036. They vest in three equal tranches between 2027 and 2029, after which Oosthuizen may choose to exercise them any time before expiration.

How many Merck (MRK) common shares does Johannes Oosthuizen hold after these transactions?

After the reported transactions, Johannes Oosthuizen directly holds 21,895.389 shares of Merck common stock. This figure reflects his current direct ownership position and is separate from the additional shares underlying his new options and RSU awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 11:42 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oosthuizen Johannes Jacobus

(Last) (First) (Middle)

MERCK & CO., INC.

126 EAST LINCOLN AVENUE

(Street)

RAHWAY NEW JERSEY 07065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Oncology & Int?l

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								21,895.389	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	05/05/2026		A		10,605		05/05/2027(2)	05/05/2029	Common Stock	10,605	$0	10,605	D
Stock Option (Right to Buy)	$113.15	05/05/2026		A		31,044		05/05/2027(3)	05/04/2036	Common Stock	31,044	$0	31,044	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.

2. These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.

3. The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.

	/s/ Kelly E. W. Grez, as attorney-in-fact for Johannes Oosthuizen	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)